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Abstract
Purpose Cabazitaxel, used in patients with metastatic castration-resistant prostate cancer (mCRPC), is associated with 
adverse events which may require dose reductions or discontinuation of treatment. We investigated the potential associa-
tion of single-nucleotide polymorphisms (SNPs) in genes encoding drug transporters and drug-metabolizing enzymes with 
cabazitaxel toxicity, overall survival (OS) and pharmacokinetics (PK).
Methods A total of 128 cabazitaxel-treated mCRPC patients, of whom prospectively collected data on toxicity and OS were 
available and 24 mCRPC patients with available cabazitaxel PK measurements, were genotyped using genomic DNA obtained 
from EDTA blood. The SLCO1B1 (388A > G; *1B; rs2306283 and 521 T > C; *5; rs4149056 and haplotype SLCO1B1*15), 
SLCO1B3 (334 T > G; rs4149117), CYP3A4 (*22; rs35599367), CYP3A5 (*3; rs776746), ABCB1 (3435C > T; rs1045642), 
and TUBB1 (57 + 87A > C; rs463312) SNPs were tested for their association with clinical and PK parameters by univariate/
multivariate logistic regression, log-rank test, or Kruskal–Wallis test.
Results The SLCO1B1*15 haplotype was significantly associated with a lower incidence of leukopenia and neutropenia 
(p = 0.020 and p = 0.028, respectively). Patients harboring a homozygous variant for SLCO1B1*1B experienced higher 
rate ≥ grade 3 (p = 0.042). None of the SNPs were associated with pharmacokinetics or OS.
Conclusions In this study, SLCO1B1 (SLCO1B1*15 and SLCO1B1*1B) was associated with cabazitaxel-induced adverse 
events in mCRPC patients. As the associations were opposite to previous studies in other drugs and contradicted an underly-
ing pharmacokinetic rationale, these findings are likely to be false-positive and would ideally be validated with even larger 
(pharmacokinetic) cohorts.
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Introduction
Cabazitaxel has been approved as chemotherapy for patients 
with metastatic castration-resistant prostate cancer (mCRPC) 
after progression on docetaxel [1]. Still, its administration 
is often hampered by substantial toxicity, resulting in dose 
reductions (12%), treatment delays (28%), and discontinu-
ation of treatment (18%) [1]. Most common severe adverse 
events include neutropenia (50–80%), febrile neutropenia 
(8%), leukopenia (40–70%), fatigue (4–5%), and diarrhea 
(4–6%) [1–3]. Occurrence of ≥ grade 3 neutropenia has been 
associated with higher exposure of cabazitaxel, as well as 
with a survival benefit in mCRPC patients [4, 5]. This may 
indicate that there is a delicate balance between toxic, effec-
tive, and sub-therapeutic cabazitaxel exposure. Like most 
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chemotherapeutic agents, cabazitaxel is dosed on body sur-
face area (BSA), although this still results in an inter-patient 
variability in clearance of 24% [6]. This inter-patient varia-
bility might be explained by patient-related, disease-related, 
and environmental factors [7]. Patient-related factors might 
contain different activity of proteins involved in metabolism 
or transport of cabazitaxel, which can be caused by germline 
genetic variations.
Taxanes are substrate of the transmembrane transport-
ers P-glycoprotein (P-gp, encoded by the gene ABCB1), 
OATP1B1 (SLCO1B1) and OATP1B3 (SLCO1B3) and are 
mainly metabolized by isoenzymes CYP3A4 and CYP3A5 
(80–90%) and to a lesser extent by CYP2C8 in the liver 
[8–11]. Single nucleotide polymorphisms (SNPs) in the 
genes encoding for these transporters and enzymes can 
alter protein activity and consequently result in an increased 
inter-patient variability in cabazitaxel exposure. In previ-
ous research investigating these SNPs, female CYP3A4*22 
carriers were found to be at increased risk of grade 3–4 tox-
icity during docetaxel treatment and of neurotoxicity dur-
ing paclitaxel treatment [12, 13]. In patients with advanced 
urothelial cell carcinoma (UCC) treated with cabazitaxel, 
CYP3A5*1 has been associated with a reduced risk of gas-
trointestinal toxicity and a shorter progression-free survival 
(PFS) [14]. Additionally, genetic polymorphisms in CYP3A4 
and CYP3A5 have been associated with an increased doc-
etaxel clearance [15]. ABCB1 polymorphisms were found 
to be related to increased grade 3–4 toxicity [14]. SNPs 
in SLCO1B1 and SLCO1B3 were not shown to be associ-
ated in pharmacokinetic differences in docetaxel in Euro-
pean population [16, 17]. In Asian nasopharyngeal cancer 
patients, however, carriers of a homozygous variant (GG) 
at SLCO1B3 had lower docetaxel clearance and therefore, 
higher docetaxel concentrations [18]. Polymorphisms in 
SLCO1B have not been associated with clinical outcomes 
during taxane therapy, but downregulation of the influx 
pump OATP1B3 is associated with in vitro taxane resist-
ance [11] and may therefore affect survival. Another gene 
that may play a role in taxane resistance, and possibly sur-
vival, encodes for β-tubulin isoform, the binding site of 
taxanes on microtubules. A missense polymorphism in that 
gene (TUBB1) has been identified as significantly associated 
with reduced survival in cabazitaxel-treated UCC patients 
[10, 14].
In the current study, we therefore assessed the associa-
tion of SNPs in SLCO1B1 (rs2306283 and rs4149056), 
SLCO1B3 (rs4149117), CYP3A4 (rs35599367), CYP3A5 
(rs776746), ABCB1 (rs1045642), and TUBB1 (rs463312) 
with survival and toxicity in mCRPC patients treated with 
cabazitaxel. Additionally, we assessed the association of 
these genetic variations to cabazitaxel pharmacokinetics 
(PK) in the mCRPC setting. Ultimately, better understand-
ing of mechanisms underlying inter-patient variability can 




In this exploratory post hoc analysis, docetaxel pre-treated 
mCRPC patients who had received cabazitaxel therapy 
and were included in one of the three different clinical tri-
als performed in the Netherlands between December 2011 
and June 2016 were analyzed. The three trials were the 
CABARESC trial [2], a pharmacokinetic prequel study of 
that trial (EudraCT number 2011-003346-40) [2], and the 
CABENZA trial [19].
The original CABARESC trial aimed to examine the 
effects of budesonide on cabazitaxel-induced diarrhea in 
docetaxel pre-treated mCRPC patients. Clinical data on 
toxicity and survival were prospectively collected for these 
patients. Before conducting the CABARESC trial, a prequel 
study in 18 mCRPC patients was performed to ensure that 
budesonide did not affect cabazitaxel PK [2]. Demograph-
ics and clinical outcomes of the patients included in the 
PK prequel study were obtained retrospectively from their 
medical records. In the CABENZA trial, the difference in 
cabazitaxel PK with or without concomitant enzalutamide 
was investigated in mCRPC patients eligible for cabazitaxel 
therapy. Since these patients were temporarily treated with 
the combination therapy, their clinical outcome data were 
not collected. The data of the CABARESC trial and its PK 
prequel study were used to investigate the influence of SNPs 
on clinical outcome (i.e. survival and toxicity), whereas the 
data of the monotherapy cycles in the CABENZA study and 
of the CABARESC PK prequel study were used to identify 
the effect of SNPs on PK of cabazitaxel. Details of the trial 
designs are summarized in the Supplementary Methods. All 
patients had given written informed consent and the prospec-
tive trials were performed according to the latest version of 
the Declaration of Helsinki.
Survival, toxicity, and PK
Overall survival (OS) was defined as the period between the 
date of study registration to either the date of death from 
any cause or the date at which patients were last known to 
be alive at the end of the study. Toxicity was graded when 
it increased from baseline, according to the Common Ter-
minology Criteria for Adverse Events (CTCAE) v4.3. The 
non-hematological adverse events included in this analysis 
were vomiting, nausea, diarrhea, sensory peripheral neu-
ropathy, fatigue, anorexia, alopecia, allergic reaction, and 
fever. In addition, hematological adverse events like anemia, 
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leukopenia, thrombocytopenia, neutropenia, and febrile neu-
tropenia were included. Blood samples (4 mL, lithium hepa-
rin tube) were withdrawn at 12 different timepoints over 24 h 
and analyzed by validated liquid chromatography with tan-
dem mass spectrometry methods (UP-MS/MS). PK param-
eters included in the analysis were AUC 0–24 h, Cmax and t1/2.
SNP selection
Seven potentially relevant SNPs in six genes involved in the 
metabolism or working mechanism of cabazitaxel were iden-
tified (Table 1). These polymorphisms were selected based 
on previous research reporting potential associations with 
toxicity and survival.
DNA isolation and genotyping
DNA isolation was performed in whole-blood samples col-
lected in EDTA tubes, of which 400 μL was extracted on 
the Mag-NAPure Compact instrument (Roche Diagnostics 
GmbH, Mannheim, Germany) using the Nucleic Acid Isola-
tion kit I (Roche Diagnostics GmbH, Mannheim, Germany), 
eventually resulting in 20 ng genomic DNA. This genomic 
DNA was mixed with allele-specific fluorescent-labeled 
primers and probes and a TaqMan GTXpress Master Mix 
(Applied Biosystems, Life Technologies Europe BV, Blei-
jswijk, The Netherlands) to conduct qPCR. qPCR consisted 
of 40 cycles of denaturation at 95 °C during 20 s, followed 
by annealing transpired at 92 °C for 3 s and the extension 
phase at a temperature of 60 °C for 30 s. Genotypes were 
scored by measuring allele-specific fluorescence using the 
Taqman 7500 software (Applied Biosystems, Life Technol-
ogies Europe BV, Bleijswijk, The Netherlands) for allelic 
discrimination.
Statistical analyses
The distribution of the different studied SNPs in the study 
population was tested according to the Hardy–Weinberg 
equilibrium using Chi-squared test. Polymorphisms with a 
minor allele frequency of < 1% were not analyzed. SNPs on 
the same gene were tested for linkage disequilibrium (LD) 
by calculating R2 using LDlink (https ://ldlin k.nci.nih.gov/). 
The limit for LD was set at R2 > 0.8. In Utah Residents origi-
nated from North and West Europe (CEU population), the 
SLCO1B1 studied SNPs were in partial LD, consequently 
resulting in an additional haplotype (SLCO1B1*15) [20]. 
The selected SNPs or haplotypes were fitted in the most 
appropriate model. Dominant and recessive models were 
tested against toxicity endpoints using the Fisher’s exact test 
or the Chi-squared test, depending on the size of the groups. 
Additionally, an additive model was tested for which logistic 
regression analysis was used to investigate the association 
between the studied SNPs included as categorical variables 
and toxicity. Toxicity endpoints were dichotomized at two 
cut-offs: toxicity ≥ grade 1 and toxicity ≥ grade 3. Overall 
survival (OS) was analyzed using Cox regression analysis. 
Univariable genetic associations with p < 0.1 were entered 
in multivariable analysis as dependent variable if an end 
point occurred in at least ten patients per genotype. Baseline 
Table 1  Studied SNPs
MAF minor allele frequency, WT wildtype, HT heterozygous, HOMO homozygous, Var variant SLCO1B1*15, NA not applicable
Survival/toxicity analy-
sis, n = 128
PK analysis, n = 24




SLCO1B1 rs2306283 388A > G








46 (36%); 54 (42%); 28 
(22%)
93 (73%); 33 (26%); 
2 (1%)
WT 98 (77%); Var 30 
(23%)
9 (38%); 11 (46%); 4 
(16%)
18 (75%); 6 (25%); 0 (%)
WT 19 (79%); Var 5 
(21%)
SLCO1B3 rs4149117 334 T > G NA 20,858,546 88% 1 (1%); 29 (22%); 98 
(77%)
0 (0%); 2 (8%); 22(92%)
CYP3A4 rs35599367 G > A CYP3A4*22 99,768,693 7% 110 (86%); 17 (13%); 
1 (1%)
19 (79%); 5 (21%); 0 
(0%)
CYP3A5 rs776746 G > A CYP3A5*3 99,672,916 7% 108 (84%); 19 (15%); 
1 (1%)
19 (79%); 4 (17%); 0 
(0%); Missing 1 (4%)
ABCB1 rs1045642 3435C > T NA 87,509,329 55% 29 (23%); 57 (44%); 42 
(33%)
6 (25%); 10 (42%); 8 
(33%)
TUBB1 rs463312 57 + 87A > C NA 59,022,915 7% 111 (87%); 17 (13%), 
0 (0%)
21 (88%); 3 (12%), 0 
(0%)
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factors (WHO performance status, age or hematological 
laboratory results) with p < 0.1 were added in multivariable 
analysis as independent variables. Multivariable analysis 
was performed using logistic or Cox regression analysis. 
As for the PK analysis, the influence of SNPs on cabazi-
taxel exposure was tested by the Mann–Whitney U test or 
Kruskal–Wallis test, based on the number of groups. Both 
univariable and multivariable toxicity associations with 
p < 0.1 were internally validated by bootstrapping. For this 
purpose, one thousand bootstrap samples were generated 
and the bias-corrected 95% CIs were calculated for ORs. All 
statistical analyses were performed using SPSS version 21. 
A two-sided p < 0.05 was considered significant.
Results
Patients and treatment
From a total of 281 patients included in all three trials com-
bined [2, 19], 128 patients could be analyzed for the asso-
ciation of polymorphisms with toxicity and survival and 24 
patients could be analyzed for the association with cabazi-
taxel PK (Supplementary Fig. 1). All these patients started 
3-week cabazitaxel treatment at 25 mg/m2 and received a 
median of seven cycles (IQR 4–9). Baseline characteristics 
of these patients are depicted in Table 2.
Toxicity, overall survival, and pharmacokinetics
The most relevant associations of the investigated SNPs 
with toxicity are displayed in Table 3. A total overview 
of all associations with a p value < 0.1 in the univariable 
Table 2  Baseline characteristics 
total patient cohort
IQR interquartile range, WHO PS World Health Organization performance status, PSA prostate-specific 
antigen, Hb hemoglobin, AP alkaline phosphatase, LDH lactate dehydrogenase
Characteristics Survival/toxicity analysis 
(n = 128)
PK analysis (n = 24)
Age (median, IQR) 68 (63–73) 67 (63–73)
WHO PS
 0 56 (44%) 3 (12.5%)
 1–2 72 (56%) 21 (87.5%)
Nr. previous chemotherapies
 1 114 (89%) 16 (67%)
 ≥ 2 14 (11%) 8 (33%)
Months since last therapy (median, IQR) 6.1 (2.8–11.2) 6.4 (3.4–10.0)
Lab results (median, IQR)
 PSA (µg/L) 173 (55–354) 232 (75–382)
 Hb (mmol/L) 7.7 (6.7–8.2) 7.7 (6.5–8.2)
 Albumin (g/L) 39 36–43) 42 (39–43)
 AP (U/L) 142 (96–291) 138 (82–337)
 LDH (U/L) 322 (216–480) 224 (190–316)
Table 3  Significant associations of SNPs with toxicity
OR odds ratio, WHO PS World Health Organization performance status
Endpoint Factor Genotype Univariable Multivariable
OR (95% CI) p OR (95% CI) p
Toxicity ≥ grade 3 WHO PS (1–2 vs 0)
SLCO1B1*1B (388A > G)
SLCO1B3 (334 T > G)
GG vs AA + AG













Leukopenia SLCO1B1*15 *15 vs No*15 0.371 (0.158–0.869) 0.020
Neutropenia WHO PS (1–2 vs 0)
SLCO1B1*15
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analyses is given in Supplementary Table 1. The haplo-
type SLCO1B1*15 (388A > G and 521 T > C) was associ-
ated with all grade neutropenia, even after correction for 
WHO performance status (OR 0.38, 95% CI 0.16–0.90, 
p = 0.028), and with all grade leukopenia (OR 0.37, 95% CI 
0.16–0.90, p = 0.020). The presence of a homozygous vari-
ant in SLCO1B1*1B was associated with an increased risk 
of toxicity ≥ grade 3, corrected for WHO performance score 
and SLCO1B3 334 T > G. Bootstrapping resulted in similar 
CIs in these analyses (Supplementary Table 1).
The TUBB1 128A > C variant was associated with a 
reduced OS in univariable analysis, but this association did 
not hold after correction for baseline factors (Supplementary 
Table 2). The remaining SNPs were not associated with OS. 
Moreover, none of the SNPs were associated with one of the 
pharmacokinetic parameters of cabazitaxel (Supplementary 
Table 3).
Discussion
In this exploratory pharmacogenetic analysis in men with 
mCRPC treated with cabazitaxel, several new associations 
between genetic polymorphisms and cabazitaxel-related tox-
icities were found. The haplotype (*15) of SLCO1B1 SNPs 
(388A > G and 521 T > C) resulted in a reduced incidence of 
leukopenia and neutropenia; the latter even after correction 
for WHO performance status (Table 3). As neutropenia is 
the most frequent adverse reaction of cabazitaxel treatment 
(80%) and the most common reason for cabazitaxel discon-
tinuation [21], identification of predictors for neutropenia 
is important for clinical practice. In addition, it was found 
that one mutant allele of SLCO1B1 388A > G resulted in an 
increased incidence of grade 3 (or higher grade of) toxic-
ity. The isolated hepatic expression of both OATP1B1 and 
OATP1B3 [22] leaves little room for alternative hypotheses 
than an influence of these SNPs on toxicity via increased 
systemic cabazitaxel exposure. However, this PK-based 
rationale is contradicted by the fact that none of the investi-
gated SLCO SNPs or haplotypes were significantly associ-
ated with systemic exposure. Moreover, in previous phar-
macogenetic association studies, these SLCO SNPs were not 
associated with docetaxel PK [16, 17, 23]. Ultimately, the 
observed associations are opposite to the expected working 
mechanism of the genetically varied proteins. Previously 
published literature showed that one variant G-allele at 
codon 388 of SLCO1B1 (rs2306283) increases the activity 
of the hepatic influx transporter OATP1B1, while one vari-
ant C allele at codon 521 (rs4149056) leads to a reduced 
OATP1B1 activity [24] and the haplotype SLCO1B1*15 also 
leads to reduced OATP1B1 function [20]. Therefore, the 
expected increase and decrease in toxicity are opposite to 
the observed direction of the association between the SLCO 
SNPs and toxicity. The previously reported associations of 
the SLCO1B1 SNPs with statin, sorafenib, irinotecan, and 
methotrexate toxicity show that these polymorphisms are 
truly associated with toxicity [25–28], which is in line with 
the working mechanism of the altered protein function, 
and thus in contrast with the results from this study. This 
contrast can possibly be explained by a substrate-specific 
effect of the studied SNPs, as was previously found for 
ABCB11199G > A SNP [29]. The effect of taxanes on the 
working mechanisms of the studied SLCO1B1 SNPs is an 
interesting research topic and never been performed before. 
For other taxanes, like paclitaxel and docetaxel, the role of 
SLCO polymorphisms on developing adverse events has not 
been specified either [15].
Although the studied SNPs in TUBB1 and SLCO1B3 
have been associated with survival and taxane therapy pre-
viously [14, 30], none of the SNPs remained significantly 
associated with OS in our cohort. A variant allele at TUBB1 
57 + 87A > C was associated univariably with OS, but 
correction for baseline clinical parameters disproved this 
finding.
Despite the found associations were internally validated, 
the main limitation of this study is its explorative character, 
which is refraining us from determining a causal relation of 
the found associations. Similarly, the contradictory findings 
in the SLCO polymorphisms might be attributed to coinci-
dence by multiple testing. Although this is the largest genetic 
association study in cabazitaxel-treated patients so far, the 
relatively low minor allele frequencies at some of the SNPs 
and the small number of patients in the PK analyses might 
have influenced our results, which would ideally be validated 
in even larger prospective cohorts, in which other possible 
explanations for altered cabazitaxel pharmacokinetics, e.g. 
drug-drug interactions, can also be taken into account.
Conclusions
In this study with prospectively collected data, an asso-
ciation between genetic variations in SLCO (haplotype 
SLCO1B1*15 and SLCO1B1*1B) and relevant cabazitaxel-
induced toxicity in mCRPC patients was found. However, 
these associations could not be explained by PK differences 
and, moreover, the observed effect of the SLCO1B1 SNPs 
was opposite to the expected altered working mechanism of 
the OATP1B1 protein. Therefore, larger prospective phar-
macokinetic studies are needed to investigate the role of 
variations in SLCO on systemic cabazitaxel exposure and 
eventually cabazitaxel-induced toxicity.
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